Clinical trial NCT05077137: A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Official title: A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Melanoma
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2021-10-14
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and feasibility of administering the Tetanus Diptheria Vaccine (Td) or Polio Boost Immunization (IPOL) to patients with metastatic melanoma who are receiving immune checkpoint inhibitor (IO) therapy per standard of care. Subjects will have the vaccine at cycle 4 of IO therapy and will have research blood and tissue samples collected prior to starting IO therapy, at cycle 4 prior to vaccine administration, and at 12-17 days post vaccine.


Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed advanced metastatic melanoma
2. Male or female participants who are at least 18 years of age on the day of signing informed consent
3. Participants must be planned or scheduled by their treating physician to receive PD-1 therapy or PD-1 plus anti CTLA-4 therapy as standard of care
4. Participant (or legally acceptable representative if applicable) provides written informed consent for the trial
5. Participant must have at least 1 lesion that is at least 8 mm in size and is cutaneous, subcutaneous, palpable, or amenable to ultrasound guided core biopsy. The lesion chosen for biopsy can also be a target lesion but does not have to be a target lesion
6. Adequate organ function as defined below. Standard of care labs drawn within 45 days prior to consent may be used for the purposes of determining eligibility

   1. ANC \>/= 1500/uL
   2. platelets \>/=100,000/uL
   3. Hemoglobin \>/= 9.0 g/dL

Exclusion Criteria:

1. Uveal or mucosal melanoma
2. Any women known to be pregnant or breastfeeding
3. Any prior systemic therapy for metastatic melanoma (prior surgery is allowed)
4. Known diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone or equivalent), or any other form of immunosuppressive therapy within 7 days prior to first research biopsy
5. Patients with symptomatic CNS metastases and/or carcinomatous meningitis

   a) Patients with asymptomatic, stable CNS metastases are allowed provided that they are not on \>10mg prednisone daily
6. History of or active (non-infectious) pneumonitis that required steroids
7. Active infection requiring systemic therapy
8. Known history of Human Immunodeficiency Virus (HIV) infection
9. Known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. NOTE: no testing for Hepatitis B or Hepatitis C is required
10. Known history of active TB (Bacillus Tuberculosis)
11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with subject's participation for the full duration of the study, or make it not in the best interest of the subject to participate, in the opinion of the treating physician
12. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
13. History of allogenic tissue or solid organ transplant
14. History of allergic reaction to IPOL or Td vaccine
15. Receipt of Td vaccine within 30 days prior to starting IO therapy

Primary outcomes:
measure: Number of subjects out of the proposed 25 that successfully receive the vaccine after 4 cycles of IO therapy
timeFrame: informed consent through date of vaccine (est apx 4-5 months)
measure: Safety, as measured by the change in the number and severity of adverse events deemed related to the vaccine or study procedures (blood draw and biopsies)
timeFrame: Baseline, cycle 4 of IO therapy (apx 12-16 weeks), 12-17 days post vaccine, SOC scan following vaccine (apx 8-12 weeks post vaccine)
Secondary outcomes:
measure: Preliminary efficacy, as measured by objective response rate
timeFrame: up to 36 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Georgia Beasley, MD
role: PRINCIPAL_INVESTIGATOR
References: